Eli Lilly’s Mounjaro peak sales could now top $68B – analyst; Elon Musk’s brain-chip company reels in $280M
A few months ago, BMO Capital analyst Evan Seigerman estimated Eli Lilly’s type 2 diabetes drug Mounjaro would have more than $50 billion in peak sales. On Tuesday, he bumped that estimate up to $68.7 billion.
One reason for the boost? Lilly reported Mounjaro’s consensus-busting sales in its second-quarter earnings on Tuesday, along with an anticipated FDA approval in obesity this year and his assessment of the drug’s “uninhibited” demand.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.